Reading the EBC-46 Human Trial Readouts: What Phase I and Phase II Actually Tell Us
How to read published and disclosed data from QBiotics’ Phase I and ongoing Phase II studies of tigilanol tiglate in humans, without overreaching the evidence.
Human clinical data for EBC-46 is still early-stage by oncology standards, but enough has been published or publicly disclosed that readers can start to form a grounded view of what the molecule does in people. This article walks through what the Phase I and Phase II work has actually shown, and — just as importantly — where interpretation should stop.
Phase I: establishing a safety window
The first-in-human study of intratumoural tigilanol tiglate was reported by Panizza et al. in EBioMedicine (2019), covering patients with refractory cutaneous and subcutaneous tumours. The primary findings were consistent with the canine work: local inflammation, tumour necrosis within the treated lesion, and a rapid acute phase that resolved over roughly 7–14 days. No dose-limiting systemic toxicity was reported at the doses studied. Safety was the primary endpoint; response rates are a secondary outcome in a Phase I and should be treated as such.
Phase II: multiple tumour types, expanding cohorts
Phase II activity has focused on soft tissue sarcoma, head and neck squamous cell carcinoma, and selected refractory solid tumours. Public disclosures from QBiotics describe ongoing enrolment and interim safety signals; peer-reviewed readouts have been slower to appear, which is normal for Phase II programmes of this size. Readers should be cautious about drawing efficacy conclusions from press releases; the clinical meaning of any given response rate depends heavily on the comparator, the patient population, and the follow-up duration.
What the numbers can and cannot tell you
A useful habit when reading any tigilanol tiglate readout is to separate three things: (1) the safety profile, which is well-characterised and reassuring so far; (2) the local response rate at the injected lesion, which is the primary pharmacological effect the mechanism predicts; and (3) the systemic or abscopal response, which is much harder to pin down in early-phase data and is the question Phase III will need to answer. For background on why this local-vs-systemic split matters, see our mechanism article on PKC-delta and vascular disruption.
Why this is separate from the supplement category
The clinical programme is studying a pharmaceutical-grade, intratumourally injected product. Oral blushwood berry extract supplements — such as those produced by Blushwood Health — are a different product, regulated under DSHEA, and do not rely on clinical trial results for their regulatory status. Responsible supplement brands do not point to Phase I/II pharmaceutical data as evidence for their products; the two categories are studied under different frameworks, and conflating them confuses readers.
How to follow the evidence in 2026
For anyone wanting to track new readouts without relying on press releases, the ClinicalTrials.gov registry is the most reliable public source of trial status updates. Peer-reviewed publications in PubMed remain the gold standard once data has been analysed and submitted; abstracts from ASCO and ESMO annual meetings are the usual interim venues. Reading these in combination, rather than any one in isolation, is the right approach.
A note on expectation management
Phase II results are, by design, hypothesis-generating. Even strong signals need confirmation in randomised Phase III trials before they change clinical practice. The EBC-46 clinical story is an interesting one to watch, but it is still a story about a pharmaceutical in development, not a settled therapy.
Related reading
• EBC-46 regulatory landscape 2026: Stelfonta and DSHEA
• Complete guide to EBC-46 / tigilanol tiglate
